Impact of Insulin Treatment in Diabetic Macular Edema Therapy in Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 39, Issue 1, 2015, Pages 73-77

  Matsuda, Simone ^a,b   Tam, Tiffany ^a   Singh, Rishi P ^a   Kaiser, Peter K ^a   Petkovsek, Daniel ^a   Zanella, Maria Teresa ^b   Ehlers, Justis P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aflibercept; Avastin ; Bevacizumab; Diabetic macular edema; Diabetic retinopathy; Glycated hemoglobin (A1C); Insulin therapy; Metabolic parameters; Ranibizumab; VEGF inhibitors

Indexed keywords

BEVACIZUMAB; CREATININE; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BODY MASS; CENTRAL MACULAR THICKNESS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MACULAR EDEMA; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MACULAR EDEMA; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84921274825     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2014.06.005     Document Type: Article

References (18)

1. Yau J.W., Rogers S.L., Kawasaki R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564.
2. Fox C.S., Pencina M.J., Meigs J.B., et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: The Framingham Heart Study. Circulation 2006, 113:2914-2918.
3. Implications of the Diabetes Control and Complications Trial American Diabetes Association. Diabetes 1993, 42:1555-1558.
4. Nilsson P.M. ACCORD and risk-factor control in type 2 diabetes. NEngl J Med 2010, 362:1628-1630.
5. Nathan D.M. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998, 352:832-833.
6. Mitchell P., Bandello F., Schmidt-Erfurth U., et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625.
7. Nguyen Q.D., Brown D.M., Marcus D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012, 119:789-801.
8. Sugimoto M., Cutler A., Shen B., et al. Inhibition of EGF signaling protects the diabetic retina from insulin-induced vascular leakage. Am J Pathol 2013, 183:987-995.
9. Henricsson M., Berntorp K., Fernlund P., Sundkvist G. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002, 25:381-385.
10. Poulaki V., Qin W., Joussen A.M., et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. JClin Invest 2002, 109:805-815.
11. Zapata M.A., Badal J., Fonollosa A., et al. Insulin resistance and diabetic macular oedema in type 2 diabetes mellitus. Br J Ophthalmol 2010, 94:1230-1232.
12. Do D.V., Schmidt-Erfurth U., Gonzalez V.H., et al. The DA VINCI Study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011, 118:1819-1826.
13. Rajendram R., Fraser-Bell S., Kaines A., et al. A2-year prospective randomized controlled trial of intravitreal Bevacizumab or Laser Therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012, 130:972-979.
14. Ding J., Wong T.Y. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012, 12:346-354.
15. Diep T.M., Tsui I. Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract 2013, 100:298-305.
16. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes 2011, 2:98-104.
17. Henricsson M., Nilsson A., Janzon L., Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997, 14:123-131.
18. Matsuda S., Tam T., Singh R.P., et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. JDiabetes Complications 2014, 28:166-170.